$ATXI
Avenue Therapeutics Inc Stock $atxi

$atxi Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000114420417057449 Filed on November 09, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.100M	$850.0K	$300.0K
YoY Change	266.67%	325.0%	-43.4%
% of Gross Profit
Research & Development	$5.220M	$2.000M	$210.0K
YoY Change	2385.71%	992.9%	-58.0%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$6.325M	$2.848M	$516.0K
YoY Change	1125.78%	643.6%	-49.41%
Operating Profit		-$2.848M
YoY Change		643.6%
Interest Expense	$80.00K	$106.0K	-$300.0K
YoY Change	-126.67%	19.1%	15.38%
% of Operating Profit
Other Income/Expense, Net	$82.00K	-$100.0K	-$299.0K
YoY Change	-127.42%	-37.89%
Pretax Income	-$6.240M	-$2.950M	-$820.0K
YoY Change	660.98%	446.3%	-35.94%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$6.243M	-$2.948M	-$815.0K
YoY Change	666.01%	441.91%	-36.33%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$624.6K	-$295.9K	-$98.32K
COMMON SHARES
Basic Shares Outstanding	10.27M shares	10.04M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.78M	$26.05M	$200.0K
YoY Change	10790.0%	86733.33%	1900.0%
Cash & Equivalents	$11.78M	$16.05M	$197.0K
Short-Term Investments	$10.00M	$10.00M
Other Short-Term Assets	$390.0K	$130.0K	$0.00
YoY Change		333.33%
Inventory
Prepaid Expenses		$126.0K	$0.00
Receivables
Other Receivables
Total Short-Term Assets	$22.17M	$26.18M	$200.0K
YoY Change	10985.0%	43533.33%	1900.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	-$4.000K	-$3.000K
YoY Change	-100.0%
TOTAL ASSETS
Total Short-Term Assets	$22.17M	$26.18M	$200.0K
Total Long-Term Assets	$0.00	-$4.000K	-$3.000K
Total Assets	$22.17M	$26.18M	$197.0K
YoY Change	11153.81%	43526.67%	1870.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.545M	$1.910M	$334.0K
YoY Change	362.57%	377.5%	-31.84%
Accrued Expenses	$50.00K	$80.00K	$1.750M
YoY Change	-97.14%	-94.2%	157.35%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$3.850M
YoY Change	-100.0%	-100.0%	229.06%
Total Short-Term Liabilities	$2.790M	$1.990M	$6.419M
YoY Change	-56.54%	-58.19%	162.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$2.030M
YoY Change	-100.0%	-100.0%	-24.81%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$2.030M
YoY Change	-100.0%	-100.0%	-24.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.790M	$1.990M	$6.419M
Total Long-Term Liabilities	$0.00	$0.00	$2.030M
Total Liabilities	$2.790M	$1.990M	$8.445M
YoY Change	-66.96%	-73.64%	63.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$20.66M	-$14.42M	-$8.403M
YoY Change	145.88%
Common Stock	$38.94M	$38.60M	$106.0K
YoY Change	36633.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.38M	$24.19M	-$8.248M
YoY Change
Total Liabilities & Shareholders Equity	$22.17M	$26.18M	$197.0K
YoY Change	11153.81%	43526.67%	1870.0%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q4
OPERATING ACTIVITIES
Net Income	-$6.243M	-$2.948M	-$815.0K
YoY Change	666.01%	441.91%	-36.33%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$4.270M	-$1.870M	-$70.00K
YoY Change	6000.0%	325.0%	-81.58%
INVESTING ACTIVITIES
Capital Expenditures	$0.00		$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$10.00M
YoY Change
Cash From Investing Activities	$0.00	-$10.00M	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-6.750M	240.0K
YoY Change	-100.0%	-1600.0%	-38.46%
NET CHANGE
Cash From Operating Activities	-4.270M	-1.870M	-70.00K
Cash From Investing Activities	0.000	-10.00M	0.000
Cash From Financing Activities	0.000	-6.750M	240.0K
Net Change In Cash	-4.270M	-18.62M	170.0K
YoY Change	-2611.76%	-186300.0%	1600.0%
FREE CASH FLOW
Cash From Operating Activities	-$4.270M	-$1.870M	-$70.00K
Capital Expenditures	$0.00		$0.00
Free Cash Flow	-$4.270M		-$70.00K
YoY Change	6000.0%		-81.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q3	us-gaap	Assets Assets	26176000	USD
CY2016Q4	us-gaap	Assets Assets	197000	USD
CY2017Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1914000	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	506000	USD
CY2017Q3	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	57000	USD
CY2017Q3	atxi	Accruedinterestrelatedpartycurrent Accruedinterestrelatedpartycurrent	0	USD
CY2016Q4	atxi	Accruedinterestrelatedpartycurrent Accruedinterestrelatedpartycurrent	346000	USD
CY2017Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0	USD
CY2016Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	2848000	USD
CY2017Q3	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	0	USD
CY2016Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	1000000	USD
CY2017Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	0	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6419000	USD
CY2016Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	314000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1990000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	106000	USD
CY2017Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2016Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	200000	USD
CY2017Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2016Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1826000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	1990000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	8445000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2017Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	38603000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	105000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14418000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8403000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	24186000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-8248000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26176000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	197000	USD
CY2017Q3	atxi	Common Stock Value Issuable CommonStockValueIssuable	0	USD
CY2016Q4	atxi	Common Stock Value Issuable CommonStockValueIssuable	49000	USD
CY2017Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	126000	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2000000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	183000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	848000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	200000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2848000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-383000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	89000	USD
CY2017Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	0	USD
CY2016Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	53000	USD
CY2017Q3	atxi	Fair Value Adjustments Of Convertible Notes Payable FairValueAdjustmentsOfConvertibleNotesPayable	0	USD
CY2016Q3	atxi	Fair Value Adjustments Of Convertible Notes Payable FairValueAdjustmentsOfConvertibleNotesPayable	0	USD
CY2017Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2016Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	19000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-2948000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-544000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.30
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.19
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9972663	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2848651	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2580000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1168000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2516000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	693000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5096000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1861000	USD
	us-gaap	Interest Expense InterestExpense	294000	USD
	us-gaap	Interest Expense InterestExpense	261000	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	81000	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	132000	USD
	atxi	Fair Value Adjustments Of Convertible Notes Payable FairValueAdjustmentsOfConvertibleNotesPayable	99000	USD
	atxi	Fair Value Adjustments Of Convertible Notes Payable FairValueAdjustmentsOfConvertibleNotesPayable	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	451000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	108000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6015000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2362000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.85
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5514988	shares
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	270000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	1.09
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2790674	shares
CY2016Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	250000	shares
CY2016Q3	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.025	pure
CY2016	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	49000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	948000	USD
	atxi	Stock Issued During Period Conversion Of Msa Fees Into Common Value StockIssuedDuringPeriodConversionOfMsaFeesIntoCommonValue	1000000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	34235000	USD
	atxi	Stock Issued During Period Issuance Of Warrants Under Nsc Note StockIssuedDuringPeriodIssuanceOfWarrantsUnderNscNote	750000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	200000	USD
	atxi	Change In Fair Value Of Convertible Notes Warrants ChangeInFairValueOfConvertibleNotesWarrants	15000	USD
	atxi	Modification To Interest On Fortress Note ModificationToInterestOnFortressNote	300000	USD
	atxi	Change In Fair Value Of Convertible Notes Payable ChangeInFairValueOfConvertibleNotesPayable	99000	USD
	us-gaap	Stockholders Equity Period Increase Decrease StockholdersEquityPeriodIncreaseDecrease	632000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	270000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	23000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	174000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	92000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1408000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-95000	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	360000	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	585000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-57000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
	atxi	Accrued Interest Related Party AccruedInterestRelatedParty	-46000	USD
	atxi	Accrued Interest Related Party AccruedInterestRelatedParty	121000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2534000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1559000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28387000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1575000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	15853000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	16000	USD
	us-gaap	Interest Paid Net InterestPaidNet	297000	USD
	us-gaap	Interest Paid Net InterestPaidNet	183000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	948000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	126000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	31000	USD
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	3715000	USD
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37950000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1000000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	atxi	Warrants Issued WarrantsIssued	750000	USD
	atxi	Warrants Issued WarrantsIssued	0	USD
	atxi	Extinguishment Of Fortress Compensation Accrual ExtinguishmentOfFortressCompensationAccrual	632000	USD
	atxi	Extinguishment Of Fortress Compensation Accrual ExtinguishmentOfFortressCompensationAccrual	0	USD
	atxi	Interest On Fortress Note On Modification InterestOnFortressNoteOnModification	300000	USD
	atxi	Interest On Fortress Note On Modification InterestOnFortressNoteOnModification	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	200000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	atxi	Change Fair Value Of Convertible Note Warrents ChangeFairValueOfConvertibleNoteWarrents	15000	USD
	atxi	Change Fair Value Of Convertible Note Warrents ChangeFairValueOfConvertibleNoteWarrents	0	USD
CY2015Q4	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	3000000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	70000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	200000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	200000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	300000	USD
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1.0	USD
CY2017Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	166666	shares
CY2017Q2	us-gaap	Share Price SharePrice	6.00
CY2017Q3	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	0	USD
CY2016Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	314000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	AVENUE THERAPEUTICS, INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0001644963
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Trading Symbol TradingSymbol	ATXI
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10265174	shares
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10265174	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10265174	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3257936	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3257936	shares
CY2017Q3	atxi	Common Stock Shares Issuable CommonStockSharesIssuable	0	shares
CY2016Q4	atxi	Common Stock Shares Issuable CommonStockSharesIssuable	83532	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Use of Estimates</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 14.3pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Valuation of Warrant Related to NSC Note</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 14.3pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In accordance with ASC 815 <i>Derivatives and Hedging</i>, the Company classified the fair value of the warrant (“Contingently Issuable Warrants”) that it may be obligated to issue to National Securities, Inc. (“NSC”), in connection with the transfer on October 31, 2015 of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.0</font> million of indebtedness to NSC, as a derivative liability as there was a potential that the Company would not have a sufficient number of authorized common shares available to settle this instrument. The Company valued these Contingently Issuable Warrants using a Black-Scholes model and used estimates for an expected dividend yield, a risk-free interest rate, and expected volatility together with management’s estimate of the probability of issuance of the Contingently Issuable Warrants. At each reporting period, as long as the Contingently Issuable Warrants were potentially issuable and there was a potential for an insufficient number of authorized shares available to settle the Contingently Issuable Warrants, the Contingently Issuable Warrants should be revalued and any difference from the previous valuation date would be recognized as a change in fair value in the Company’s statement of operations. On June 26, 2017, the warrants were issued (See Note 6).</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	5000000	USD
CY2017Q3	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	3500000	USD
CY2017Q3	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	100000	USD
	atxi	Agreement Description Terms AgreementDescriptionTerms	(i) issue annually to Fortress, on the anniversary date of the Founders Agreement, shares of common stock equal to two and one half percent (2.5%) of the fully-diluted outstanding equity of Avenue at the time of issuance; (ii) pay an equity fee in shares of Avenue common stock, payable within five (5) business days of the closing of any equity or debt financing for Avenue or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when Fortress no longer has majority voting control in Avenues voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of Avenues annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), Fortress will be paid a one-time change in control fee equal to five (5x) times the product of (i) net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0183	pure
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.29
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M17D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8	pure
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	20000	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	20000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.29
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2017Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16050000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	197000	USD
CY2017Q3	us-gaap	Short Term Investments ShortTermInvestments	10000000	USD
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	USD
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	10000000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	8000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3000000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-2848000	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	1583000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	40000	USD
	atxi	Repurchase Of Common Stock RepurchaseOfCommonStock	0	USD
	atxi	Repurchase Of Common Stock RepurchaseOfCommonStock	10000	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	1000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30000	USD
CY2017Q3	atxi	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	76000	USD
CY2016Q4	atxi	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	1348000	USD
CY2017Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	5000000	USD

Files In Submission

Name	View Source	Status
0001144204-17-057449-index-headers.html	Edgar Link	pending
0001144204-17-057449-index.html	Edgar Link	pending
0001144204-17-057449.txt	Edgar Link	pending
0001144204-17-057449-xbrl.zip	Edgar Link	pending
atxi-20170930.xml	Edgar Link	completed
atxi-20170930.xsd	Edgar Link	pending
atxi-20170930_cal.xml	Edgar Link	unprocessable
atxi-20170930_def.xml	Edgar Link	unprocessable
atxi-20170930_lab.xml	Edgar Link	unprocessable
atxi-20170930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv478531_10q.htm	Edgar Link	pending
tv478531_ex31-1.htm	Edgar Link	pending
tv478531_ex31-2.htm	Edgar Link	pending
tv478531_ex32-1.htm	Edgar Link	pending
tv478531_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATXI
Avenue Therapeutics Inc Stock $atxi

2017 Q4 Form 10-Q Financial Statement

#000114420417057449 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATXI Avenue Therapeutics Inc Stock $atxi

2017 Q4 Form 10-Q Financial Statement

#000114420417057449 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATXI
Avenue Therapeutics Inc Stock $atxi